Glibenclamide Tablets

This product is a hypoglycemic drug. 1. It stimulates the pancreatic islet beta cells to secrete insulin, provided that the islet beta cells also have a certain ability to synthesize and secrete insulin. 2. It inhibits hepatic glycogenolysis and gluconeogenesis by increasing portal vein insulin levels or acting directly on the liver, reducing the generation and output of glucose by the liver. 3. It may also increase the sensitivity of extrapancreatic tissues to insulin and the utilization of sugar (probably mainly through post-receptor effects). Therefore, the overall effect is to lower fasting blood sugar and postprandial blood sugar.

The main ingredient of this product is glibenclamide.

This product is white tablets.

It is suitable for mild and moderate type 2 diabetes mellitus that is not effectively controlled by diet alone. The patient's pancreatic β cells have a certain insulin secretion function and there are no serious complications.

Oral administration starts with 2.5 mg, once before breakfast or before breakfast and lunch. For mild cases, 1.25 mg, three times a day, before meals. After 7 days, increase the dosage by 2.5 mg per day. The general dosage is 5-10 mg per day, and the maximum dosage does not exceed 15 mg per day.

1. There may be diarrhea, nausea, vomiting, headache, stomach pain or discomfort; 2. Less common are rashes; 3. Rare but serious symptoms include jaundice, liver damage, bone marrow suppression, granulocytopenia (manifested as sore throat, fever, infection), thrombocytopenia (manifested as bleeding, purpura), etc.

The following situations should not be used: 1. Type I diabetic patients. 2. Type II diabetic patients with ketoacidosis, coma, severe burns, infection, trauma, major surgery and other stressful conditions. 3. Patients with liver and kidney dysfunction. 4. Patients allergic to sulfonamides. 5. Patients with leukopenia.

Precautions for children: Not clear. Precautions for pregnancy and lactation: Pregnant women should not take it. Animal experiments and clinical observations have shown that sulfonylurea hypoglycemic drugs can cause stillbirth and fetal malformation. Precautions for the elderly: Elderly patients and those with renal insufficiency have reduced metabolism and excretion capabilities of this type of drug. This product has a relatively strong hypoglycemic effect, so it is not suitable to use this product. Other sulfonylurea hypoglycemic drugs with shorter action time can be used.

1. When taken with alcohol, it can cause abdominal cramps, nausea, vomiting, headache, facial flushing and hypoglycemia. 2. When used with beta-blockers, it can increase the risk of hypoglycemia and mask the symptoms of hypoglycemia, such as increased pulse rate and blood pressure; the possibility of causing this situation is low when using a small amount of selective beta-blockers such as atenolol and metoprolol. 3. Chloramphenicol, guanethidine, insulin, monoamine oxidase inhibitors, phenylbutazone, hydroxyphenylbutazone, probenecid, salicylates, and sulfonamides with this product can enhance the hypoglycemic effect. 4. Adrenal cortical hormones, epinephrine, phenytoin sodium, thiazide diuretics, and thyroxine can increase blood sugar levels. When used with this class of drugs, the dosage of this class of drugs may need to be increased. 5. When coumarin anticoagulants are used with this class of drugs, the plasma concentrations of each other will increase at first, but then the plasma concentrations of each other will decrease, so the dosage of both needs to be adjusted.

Keep tightly closed.

2.5mg

24 months.